AstraZeneca

AstraZeneca on AWS: Amazon Bedrock agentic Development Assistant for clinical trials

AstraZeneca · Drug discovery · AWS

AstraZeneca is a global, science-led biopharmaceutical company focused on discovery, development and commercialization of prescription medicines. The company uses AWS to support research through commercialization, and specifically applies Amazon Bedrock to accelerate clinical trials by combining structured and unstructured data. An agentic AI-powered Development Assistant gives clinical, regulatory, safety, and quality teams conversational access to trusted insights in seconds.

Multi-agentProduction

AstraZeneca Accelerates Drug Development with Amazon Bedrock Agents

AstraZeneca · Patient engagement · AWS

AstraZeneca developed Development Assistant, an AI tool using Amazon Bedrock Agents with multi-agent architecture for fast natural language querying of clinical, regulatory, safety, and quality data. The solution unifies structured and unstructured data sources to provide transparent, actionable insights supporting faster decision-making in drug development. Multi-agent AI architecture routes queries to specialized agents for context-aware, high-performance responses across clinical trial and R&D domains. Development Assistant reduced insight generation time from hours to minutes and scaled to 1,000+ users, breaking down domain silos across pharmaceutical R&D. The tool provides transparent data source referencing and is progressing toward expansion across broader R&D functions to accelerate medicine development pipeline.

Multi-agentScaled Production

AstraZeneca and Novartis Scale AI Across Pharma Value Chain

AstraZeneca · Patient engagement · Microsoft + AWS

This article provides a comprehensive overview of how leading pharmaceutical firms—including AstraZeneca, Novartis, Sanofi, GSK, Genentech, and AbbVie—are integrating Microsoft technologies such as Azure AI, Machine Learning, Cognitive Services, and Power Platform to transform drug development and operations. Real-world examples cover AI-powered drug target identification, generative molecule design, clinical trial acceleration, pharmacovigilance, supply chain optimization, and patient engagement via chatbots. The piece details both the tangible business benefits (shortened timelines, reduced costs, improved trial precision, and better patient outcomes) and persistent challenges such as data fragmentation, legacy systems, regulatory complexities, and change management. Strategic priorities for CIOs and IT leaders on how to industrialize AI, ensure enterprise-wide adoption, and promote responsible, cross-functional scaling of Microsoft technologies are emphasized. The article highlights collaborations like AstraZeneca’s enterprise AI roadmap, Novartis-Microsoft innovation lab, and Sanofi’s infrastructure modernization to demonstrate mature, scalable uses of cloud-based AI. Challenges with data interoperability, legacy infrastructure, talent and cultural adoption, and regulatory risk are addressed alongside solutions such as human-in-the-loop designs, explainable AI, and real-time learning cycles aligned with scientific and compliance goals.

Pilot

AstraZeneca accelerates drug discovery and clinical insights with AI

AstraZeneca · Drug discovery · Microsoft

AstraZeneca, a global pharmaceutical leader, uses advanced AI and generative AI models on Microsoft Azure to fast-track drug discovery and development at its R&D center in India. Leveraging AI-driven models for protein folding, structure-guided drug design, and antibody discovery, the company improves disease understanding, medicinal target identification, and clinical prediction accuracy. AI and ML tools extract insights from large clinical trial datasets and safety/efficacy analytics, while federated learning enables collaborative model improvement across distributed data sources without compromising privacy. The Azure infrastructure supports intensive compute needs, helping AstraZeneca reduce discovery timelines and increase success rates for new medicines, ultimately driving innovation in the pharma sector.

Pharma Investment in AI for Drug Discovery

Janssen · Drug discovery · Microsoft

Pharma companies are increasingly investing in AI to enhance computer-aided drug design (CADD) and reduce drug development time and costs, creating a multibillion-dollar market. Firms like Janssen, AstraZeneca, and Pfizer leverage AI for virtual screening and de novo drug design.